|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Five Things Urologists Need to Know About Bladder and Kidney Cancer in 2025 "Presentation" |
| Gautam Jayram, MD |
| Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer, adjuvant pembrolizumab for high-risk renal cell carcinoma, and CA9 PET imaging for kidney cancer. |
|
|
|
|
|
|
|
|
|
|
|
|
Highlights in Non-Prostate GU Oncology from ESMO 2024
|
|
Ignacio Duran, MD, PhD
|
| Sam Chang interviews Ignacio Duran about the highlights of ESMO 2024 in non-prostate genitourinary oncology. Dr. Duran discusses key findings in kidney and bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| A New Era in the Perioperative Management of Muscle-Invasive Bladder Cancer
|
| Max R. Kates, MD
|
| Max Kates highlighted two disruptive studies reshaping the perioperative management of muscle-invasive bladder cancer (MIBC). The AMBASSADOR trial demonstrated a disease-free survival (DFS) benefit with adjuvant pembrolizumab, reinforcing its role in multidisciplinary care. Additionally, an AI model integrating histopathology, cell types, and gene expression improved prediction of complete response (CR) to neoadjuvant chemotherapy, supporting bladder preservation strategies.
|
|
|
|
|
|
| Scientific Congress Highlights: Genitourinary Tumors, Non-Prostate
|
| Ignacio Duran, MD, PhD
|
| Ignacio Duran discusses key studies in non-prostate genitourinary cancers highlighting the limitations of sequencing immune checkpoint inhibitors in mRCC, reinforcing TKIs as standard care upon progression. In non-clear cell RCC, ipilimumab plus nivolumab showed improved 12-month survival versus standard care in the SUNNIFORECAST trial. For MIBC, innovative approaches like TAR-200 plus cetrelimab and ctDNA-guided post-cystectomy immunotherapy demonstrated promising outcomes, while durvalumab with chemotherapy in the NIAGARA trial improved pathologic complete response and event-free survival rates.
|
|
|
|
|
|
|
|
|
|
|
| Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA) |
| Thomas B. Powles, MBBS, MRCP, MD |
| The NIAGARA trial, presented at ESMO 2024, demonstrated that adding perioperative durvalumab to neoadjuvant cisplatin-based chemotherapy significantly improved event-free survival and overall survival in patients with cisplatin-eligible muscle-invasive bladder cancer. Pathologic complete response analysis also favored durvalumab, reinforcing its potential as a new standard of care. The combination was well-tolerated, with no new safety concerns or significant delays in surgery. |
|
|
|
|
|
| Identification of Bladder Cancer Patients That Could Benefit from Early Post-Cystectomy Immunotherapy Based on Serial Circulating Tumour DNA Testing: Preliminary Results from the TOMBOLA Trial |
| Jørgen Bjerggaard Jensen, MD |
| The TOMBOLA trial, presented at ESMO 2024, explored the use of serial circulating tumor DNA (ctDNA) testing to guide post-cystectomy immunotherapy in patients with muscle-invasive bladder cancer (MIBC). Preliminary results showed that ctDNA status is a reliable marker for recurrence risk, with 55% of ctDNA-positive patients converting to ctDNA-negative and no visible disease after immunotherapy. |
|
|
|
|
|
| Prospective Randomized Phase II Trial of Ipilimumab + Nivolumab Versus Standard of Care in Non-Clear Cell RCC: Results of the SUNNIFORECAST Trial
|
| Lothar Bergmann, MD
|
| The SUNNIFORECAST trial demonstrated that ipilimumab + nivolumab significantly improved 12-month overall survival and objective response rates compared to standard care in patients with advanced non-clear cell RCC. While progression-free survival did not differ significantly, benefits were notable in PD-L1-positive and lymph node-positive subgroups, highlighting dual checkpoint inhibitors as a promising new standard for this rare disease. Further research is needed to refine treatment strategies for these heterogeneous entities.
|
|
|
|
|
|
| TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Cisplatin-Based Chemotherapy: Interim Analysis of SunRISe-4 |
| Andrea Necchi, MD |
| The SunRISe-4 interim analysis showed that neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab significantly improved pathologic complete response and pathologic objective response rates compared to cetrelimab monotherapy in patients with muscle-invasive bladder cancer (MIBC) ineligible for or refusing cisplatin-based chemotherapy. The combination had a manageable safety profile, with most adverse events being low-grade, and highlighted the potential of TAR-200 to enhance checkpoint inhibition as a novel approach for MIBC treatment. |
|
|
|
|
|
|
|
|
|
|
|
